Aileron Therapeutics is a biotechnology business based in the US. Aileron Therapeutics stocks (ALRN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.11 – an increase of 13.4% over the previous week. Aileron Therapeutics employs 9 staff and has a market cap (total outstanding stock value) of $39.9 million.
Finder's Pick for
Beginners
Finder's Pick for
Free Trades
Finder's Pick for
Commodity Stocks
Finder's Pick for
Global Trading
| Latest market close | $0.44 |
|---|---|
| 52-week range | $0.32 - $1.40 |
| 50-day moving average | $0.49 |
| 200-day moving average | $0.70 |
| Wall St. target price | $3.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.31 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $0.44 from 2022-05-20
| 1 week (2022-05-11) | N/A |
|---|---|
| 1 month (2022-04-21) | -18.00% |
| 3 months (2022-02-18) | N/A |
| 6 months (2021-11-22) | -37.58% |
| 1 year (2021-05-21) | -63.93% |
|---|---|
| 2 years (2020-05-21) | -41.34% |
| 3 years (2019-05-21) | 1.15 |
| 5 years (2017-05-18) | N/A |
| Gross profit TTM | $-17,008,000 |
|---|---|
| Return on assets TTM | -33.4% |
| Return on equity TTM | -56.62% |
| Profit margin | 0% |
| Book value | $0.40 |
| Market capitalisation | $39.9 million |
TTM: trailing 12 months
We're not expecting Aileron Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Aileron Therapeutics's shares have ranged in value from as little as $0.32 up to $1.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aileron Therapeutics's is 2.5716. This would suggest that Aileron Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007.
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.
Read more…
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
Read more…
Here’s what you need to know about investing in the propane industry, including 3 popular propane stocks to watch.
Read more…Learn more about apps like Wealthsimple to find the best trading platform for your unique set of needs.
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.
Steps to owning and managing ENT stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing KAMBI stock, with 24-hour and historical pricing before you buy.
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
Steps to owning and managing RSI stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing PBTHF stock, with 24-hour and historical pricing before you buy.
Everything we know about the Hanover Bancorp, Inc. IPO, plus information on how to buy in.
Everything we know about the PrimeBlock IPO, plus information on how to buy in.
Everything we know about the Actelis Networks IPO, plus information on how to buy in.
